Yulistiani Yulistiani
Faculty Of Pharmacy, Universitas Airlangga, Surabaya

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search

IDENTIFIKASI PROBLEMA OBAT DALAM PHARMACEUTICAL CARE Yulistiani, .; Suharjono, .; Hasmono, Didik; Khotib, Junaidi; Sumarno, .; Rahmadi, Mahardian; Sidharta, Bambang
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol 4, No 1 (2008)
Publisher : Indonesian Research Gateway

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Pharmaceutical care is a colaborative process which goal is to prevent, identify, and solve the  drug problem. Pharmacists is the one who responsible to pharmaceutical care, to assure the safety and effectiveness of drug use. This works was aimed to identify and analyze drug problems happened during pharmaceutical care. Data was collected from Dr.  Syaiful Anwar Hospital Malang, from 1 Januari until 31 August 2006. This was a prospective study (n=138) with descriptive analysis. From the results it can be concluded that drug problems happened during pharmaceutical care in Dr. Syaiful Anwar Hospital Malang consist of: Drug Adverse Reaction (non-elergy side effect 15.22% and toxic effect 3.62%), error in drug choice (untreated indication 18.12%, unappropriate drug to indication 11.59%, unclear drug use 4.35%, unappropriate drug duplication 1.45%), contraindication 0.72%, dosing problem (overtherapy dose 22.46%, overlength therapy 2.90%, subtherapy dose 0.72%), drug interaction (potential interaction 138 cases, manifested interaction 8 cases), and others (patient uncontentment 10.14% and patient unproper care about his/her own disease/therapy 4.35%). ABSTRAKPharmaceutical care merupakan proses kolaboratif yang bertujuan untuk mencegah, mengidentifikasi, dan menyelesaikan problema obat. Dalam pelaksanaan, pharmaceutical care merupakan tanggung jawab profesional farmasis untuk menjamin penggunaan obat yang aman dan efektif dalam meningkatkan kualitas hidup pasien.  Penelitian ini bertujuan untuk mengidentifikasi dan menganalisa problema obat yang terjadi dalam pharmaceutical care. Penelitian dilakukan di Rumah Sakit Umum Dr. Syaiful Anwar Malang periode 1 Januari s/d 31 Agustus 2006, merupakan penelitian observasional-data prospektif (n=138) dengan analisis deskriptif. Dari hasil penelitian dapat disimpulkan bahwa macam problema obat yang terjadi meliputi : Reaksi obat yang tidak dikehendaki terdiri dari: efek samping non alergi (15,22%), efek toksik (3,62%); pemilihan obat terdiri dari: obat tidak diresepkan tetapi indikasi jelas (18,12%), obat tidak sesuai indikasi (11,59%), indikasi penggunaan obat tidak jelas (4,35%),duplikasi obat tidak sesuai (1,45%), Kontraindikasi (0,72%); pemberian dosis terdiri dari: dosis terlalu tinggi (22,46%), durasi terapi terlalu panjang (2,90%), dosis terlalu rendah (0,72%); interaksi obat terdiri dari: interaksi potensial 138 kejadian (n=138), manifestasi interaksi (8 kasus); dan problema lain (ketidakpuasan pasien terhadap terapi yang diberikan (10,14%) dan kurangnya perhatian/kesadaran pasien terhadap kondisi/ penyakitnya (4,35%).
Effects of Probiotics and Vitamin B Supplementation on IFN-γ and IL-12 Levels During Intensive Phase Treatment of Tuberculosis Budi Suprapti; Suharjono Suharjono; Rahmawati Raising; Yulistiani Yulistiani; Zamrotul Izzah; Wenny Putri Nilamsari; Prastuti Asta Wulaningrum; Arief Bachtiar
Indonesian Journal of Pharmacy Vol 29 No 2, 2018
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1643.076 KB) | DOI: 10.14499/indonesianjpharm29iss2pp80

Abstract

Tuberculosis is an acute infectious disease that primarily affects the lungs. Probiotics supplementation can increase the number and activity of NK cell in peripheral blood by modulation of IL-12, thus increasing IFN-γ production by Th1 response. Vitamin B1 acts on macrophages and affects neutrophil motility. Vitamin B6 is associated with the release of cytokines and the responsiveness of NK cells, while vitamin B12 affects to lymphocytes, Tcell proliferation, CD4+ ratios, and NK cell activity. To analyze the effects of probiotics and vitamin B1, B6, B12 supplementation on IFN-γ and IL-12 levels during intensive phase of antituberculosis treatment. The study was pre-post test randomised control by time series. The control group was TB patients with standard therapy of antituberculosis and vitamin B6, while the intervention group was TB patients receiving therapy plus once daily probiotics and vitamin B1, B6, B12supplementation during the intensive phase. Blood samples were withdrawn at baseline, one month, and two months after therapy to measure plasma IFN-γ and IL-12 levels using the ELISA method. Twenty two patients were divided equally into two groups. There was a tendency to greater increase of IFN-γ in the first month of the intervention group, followed by a significant decline after two-month therapy (p < 0.05). In both groups there was a rise in IL-12 levels after one month followed by a decrease in the second month (p > 0.05). However, the percentage was higher in the supplementation group. Adding probiotics and vitamins B1, B6, B12 could improve immune response through IL-12 and IFN-γ modulation during intensive phase therapy.
Analysis of Methyldopa Therapy on sFlt-1 Antiangiogenic Levels in Patients with Severe Preeclampsia Teri Wina Herwati; Yulistiani Yulistiani; Eddy Zarkaty M
Folia Medica Indonesiana Vol. 54 No. 1 (2018): March
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (173.465 KB) | DOI: 10.20473/fmi.v54i1.8052

Abstract

Methyldopa is the first-line drugs to treat hypertension in pregnancy. It can decrease blood pressure in preeclampsia by affecting a2-adrenoreceptors in central nervous system. However, it could also act by decreasing  production of sFlt-1 antiangiogenic protein levels involved in the pathophysiology of hypertention  in preeclampsia. The purpose of this study was to analyze methyldopa therapy on sFlt-1 antiangiogenic levels in the plasma of pregnant women with severe preeclampsia at the Obstetric Departement, Haji Hospital, Surabaya. This was a prospective study with observational cross-section study design. The sFlt-1 angiogenic levels were observed before and after (48 hours) methyldopa administration in severe preeclampsia patient with or without complications in the period of August to October 2016. Patient received methyldopa 250 mg or 500 mg, three times a day for clinical indications according a standard protocol. The study was approved by the ethical committee of Haji Hospital, Surabaya. There were 19 patients with preeclampsia who met the inclusion criteria, showed a decrease in the levels of sFlt-1 before and 48 hours after methyldopa therapy. Levels of sFlt-1 before methyldopa therapy in a dose of 250 mg was 10.15±10.00 (2.55-34.70) ng/ml and after therapy 8,37±9,20 (0.72-9.20) ng/ml, with a percentage decrease 17.54%. sFlt-1 levels before methyldopa therapy in a dose of 500 mg was 8.05±7.07 (2.55-20.76) ng/ml, after  therapy 4.50±2.90 (2.19-9.95) ng/ml, with a percentage decrease 44.16%. Methyldopa therapy could decrease sFlt-1 levels of antiangiogenic factor in patients with severe preeclampsia.
Children with Standard Risk Acute Lymphoblastic Leukemia in Induction And Consolidation Phase Adinugraha Amarullah; Didik Hasmono; IGD Ugrasena; Yulistiani Yulistiani
Folia Medica Indonesiana Vol. 54 No. 1 (2018): March
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (247.886 KB) | DOI: 10.20473/fmi.v54i1.8054

Abstract

Prednisone has an important role in the therapy of patient with standard risk ALL. Patients with standard risk ALL receiving high dose prednisone as therapy and supraphysiology dose of prednisone are expected to cause suppression in HPA-axis (Hypothalamic Pituitary Adrenal axis). This suppression could reduce immune system in children with ALL and increase infection risk because reduction of cortisol level. In Indonesia, we did not find study about the incident of adrenal suppression after high dose prednisone therapy, especially in induction to consolidation phase ALL patient. The aim of this study was to analyze adrenal suppression after high dose prednisone therapy on children with standard risk acute lymphoblastic leukemia in induction and consolidation phase. This study has received a certificate of Ethical Clearance No. 588/Panke.KKE/X/2016, a longitudinal observational, prospective, non-randomized trial involving children with ALL who received prednisone for 49 days during the induction phase. We collected and compared laboratory result of cortisol level in children with ALL and received prednisone therapy during induction to consolidation phase. Sample was taken at week 0,4,5,6,7,8,10,12 in the course of ALL chemotheraphy Indonesian protocol year 2013. Serum was examined using methods CLIA ADVIA Centaur® XP. Between June 2016 – January 2017, 13 patients (8 males, 5 females) were included in this study. Decrease of cortisol level after prednisone therapy occured in week-10 as much as 53% compared with week-0  (p=0.027). Cortisol level increased 64% of week-12 compared with week-10 (p=0.003). In conclusion, high dose prednisone is not significant to causing adrenal suppression in induction phase of ALL patients, and the reducing cortisol level is reversible.
Analysis of High Dose and Long-Term Prednisone Therapy on Trap 5B Level Change in Children with Steroid Sensitive Nephrotic Syndrome Dessy Surya Setyani; Mariyatul Qibtiyah; Ninik Asmaningsih; Yulistiani Yulistiani
Folia Medica Indonesiana Vol. 54 No. 2 (2018): June
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (222.891 KB) | DOI: 10.20473/fmi.v54i2.8861

Abstract

Nephrotic syndrome is a condition which is characterized by protein leakage from the blood to the urine through glomeruli. It leads to hypoproteinemia and generalised oedema. Patients with nephrotic syndrome need high dose and long term glucocorticoid such as prednisone. High dose and long term glucocorticoid can increase bone resorption. Biological marker is a valuable tool to evaluate efficacy of therapy. TRAP 5B is a sensitive biological marker for bone resorption because it reflects the number of osteoclasts. TRAP 5B is not affected by renal dysfunction and food. It also has a low diurnal variation than other bone resorption marker. The aim of this study was to analyze the changes of TRAP 5B levels at induction and alternate phase in children with steroid sensitive nephrotic syndrome. This observational prospective study was conducted from May to October 2016. Venous blood samples obtained at 08.00-10.00 am. TRAP5B levels were measured before and after induction phase and after alternate phase using ELISA. Fifteen patients were included in this study (60% boys). Majority of their age was 6 - <12 years and 40% were dependent steroid NS. TRAP 5B serum levels in induction phase increased by 37.41%±56.22%. In alternate phase, TRAP 5B serum levels increased by 28.75%±66.55% compared to the induction phase. However, the level change of both phases were not significant. As a conclusion, TRAP 5B levels increased in induction and alternate phase after high dose and long-term prednisone treatment in nephrotic syndrome.
Analysis of Prophylactic Antibiotics Usage in Caesarean Section Delivery Binti Muzayyanah; Yulistiani Yulistiani; Didik Hasmono; Nuraida Wisudani
Folia Medica Indonesiana Vol. 54 No. 3 (2018): September
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (186.428 KB) | DOI: 10.20473/fmi.v54i3.10004

Abstract

Caesarean section is the delivery through a surgical incision in the abdomen and uterus with various risks, such as Surgical Site Infection (SSI) which either occurs rapidly (24-48 hours postoperatively) or delayed. To reduce the risk of various post-cesarean section infections, prophylactic antibiotics are given. The administration of prophylactic antibiotics with recommended regimens, such as in developed countries as in the United States and Europe, with first generation of cephalosporins has not been applied in Dr. Iskak Hospital, Tulungagung. This hospital still used other types of antibiotics, such as cefotaxime or ceftriaxone. In addition, for several reasons, prophylactic antibiotics were continued with other antibiotics to reduce the risk of delayed infection. This study was designed to analyze the effectiveness of prophylactic antibiotics as recommended in cesarean section. This was a prospective observational study with consecutive sampling type, examined 41 mothers with cesarean section at the Department of Obstretics and Gynecology, Dr. Iskak Hospital, Tulungagung, Indonesia. This study was conducted from May to July, 2017. The results of the study showed that the effectiveness of prophylactic antibiotic use was 98% based on the clinical parameters and maternal laboratory outcome, which showed that SIRS was in normal category. Whereas, there was one mother (2%) who had SSI on day 10 postoperatively.
Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia Reta Anggraeni Widya; Susanto Nugroho; Sri Winarsih; Yulistiani Yulistiani
Folia Medica Indonesiana Vol. 55 No. 1 (2019): March
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (292.058 KB) | DOI: 10.20473/fmi.v55i1.24287

Abstract

Cytotoxic chemotherapy suppresses the hematopoietic system, and the most serious hematologic toxicity is neutropenia. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome. Filgrastim is used to increase neutrophils level whose therapeutic effect is unknown. The effectiveness of filgrastim is based on the ANC level pre- and post-therapy. This study aimed to analyze the use of filgrastim on ANC level changes in acute leukemia children with neutropenia, and to analyze the patient that achieve ANC level’s targeted therapy = 1000 cell/mm3. A prospective observational study with a longitudinal design was conducted from June to October 2016. The inclusion criteria of the study were patients who diagnosed acute leukemia with neutropenia and received filgrastim 10 µg/kgBW for 3, 4, 5 days. Patients’ ANC levels were measured before and after filgrastim therapy. This study has been approved its ethical clearance by Dr. Saiful Anwar Hospital, Malang. Data were obtained on the basis of neutropenic episodes, followed by 7 episodes of obtaining filgrastim for 3 days, 1 episode of obtaining filgrastim for 4 days, and 7 episodes of obtaining filgrastim for 5 days. Thus, it consists of 15 episodes. In 3 days, ANC levels increased by 9.5 fold from 381.3 ± 91.8 cell/mm3 to 3984.9 ± 426.8 cell/mm3, but in 5 days, ANC levels decreased by 0.9 fold from 200.9 cell/mm3 ± 98.2 to 189.7 ± 14.2 cell/mm3. Filgrastim was able to increased the ANC levels around nine fold for 3 days of theraphy. There were 53% neutropenia patients who achieved the goal of therapy. Filgrastim therapy with dose 10 µg/kgBW for 3 to 5 days has been able to reach the therapeutic target of 53% in acute leukemia children with neutropenia. The increased levels of ANC maximum was reached on the third day with increased levels of 9.5 fold.
Analysis of IFN-gamma and IL-10 Levels as Markers of Inflammation and Response Therapy of Anti-Tuberculosis in MDR Lung TB Patients Herni Setyawati; Soedarsono Soedarsono; Yulistiani Yulistiani; Umi Fatmawati
Folia Medica Indonesiana Vol. 55 No. 4 (2019): December
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (317.191 KB) | DOI: 10.20473/fmi.v55i4.24394

Abstract

Multidrug-Resistant Tuberculosis (MDR TB) is caused by an organism that is resistant to at least isoniazid and rifampisin, the two most potent TB drug. Immune response to against Mycobacterum tuberculosis infection is related to the function of immunity. The function of interferon-γ (pro-inflammatory) is to activate macrophages, to stimulate antimicrobial molecules (to reactive oxygen species and nitric oxide), and to inhibits interleukin-10. Interleukin-10 function is to triggers humoral immunity, to inhibit IFN- γ. This study aimed to analyze level changes and the correlation with clinical data, also months of MDR TB patients who received standard OAT therapy. This was an observational study using cross sectional design. There were 29 patients who received standard MDR TB OAT therapy from 1-24 months, who met the inclusion criteria. Then, the patients were divided based on duration of the therapy, which are the initial/intensive and advanced phase. The initial phase divided into 2: first one is for 1-4 months therapy’s time (5 patients) and the second one is for more than 4-8 months (6 patients). Then, the advanced group divided into two groups again, which are third group with more than 8-16 months (13 patients) and fouth group with more than 16-24 months (5 patients). Then, measured serum concentration IFN-γ, IL-10 at the start of the study and 4 weeks later with the ELISA method. This research during the period July-December (6 months). IFN-γ post concentrations were decreased by 39.14 ± 139.12 pg/mL (p > 0.05). The concentration of IL-10 was decreased by 33.93 ± 109.20pg/mL (p>0.05). Based on the TB score bandim method during pre and posts results were 1 patient experienced severity change from severity class 1 to 2, 1 patient from severity class 2 to 1, 1 patient remained in severity 2 and 26 patient remained in severity 1. The results showed that serum IFN-γ and IL-10 levels in initial/intensive and advanced phase patients who received MDR TB regiment after four weeks did not changed,
Effectivity of Erythropoietin-Alpha between Fixed- and Adjusted-Dose in Chronic Kidney Disease Patients With Anemia on Hemodialysis Mida Purwiningtyas; Yulistiani Yulistiani; Budi Suprapti; Bayu Dharma Santi
Folia Medica Indonesiana Vol. 55 No. 4 (2019): December
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (199.38 KB) | DOI: 10.20473/fmi.v55i4.24494

Abstract

Anemia is a common complication in chronic kidney disease (CKD) patient with hemodialysis. The cause of anemia is mainly due to erythropoetin deficiency because the kidneys as a erythropoetin producer are damaged. The most appropriate management of anemia in CKD with hemodialysis is the administration of Erythropoietin Stimulating Agent (ESA) or erythropoetin (Epo). The effectiveness of Epo therapy is influenced by the type of Epo used, the dose of Epo given, the route and frequency of Epo administration, as well as several conditions that affect it such as infection or inflammation, absolute and functional iron deficiency, and malnutrition. Therapeutic targets can be achieved if the dose given is in accordance with the needs of the patient, based on the patient's weight The purpose of this study was to determine the differences in the achievement of Epo-alpha fixed-dose administration compared with adjustment-dose in patients with CKD anemia with hemodialysis after administration of Epo-alpha for 4 weeks in outpatient poly hemodialysis units at Bhayangkara H.S Hospital. Samsoeri Mertojoso Surabaya. In this study, there were 20 patients who met the inclusion criteria (15 male and 5 female) divided into 2 groups, 10 patients in the fixed-dose group and 10 patients in the adjustment-dose group. In the fixed-dose group with a adequacy level of 132.25 ± 29.17, the average Hb change achievement was 0.68 ± 0.63 g / dL (p=0.008), whereas in the adjustment-dose group the achievement of the average Hb change the mean was 1.09 ± 0.82 g / dL (p=0.002). For the Hct parameter, the average Hct change in the fixed-dose group was 2.77 ± 2.23% (p=0.004), while in the adjustment-dose group the average Hct change achievement was 4.02 ± 2.63 g / dL (p=0.001). There was no difference in the achievement of the effectiveness of Epo on the two parameters Hb (p=0.224) and Hct (p=0.256) in the fixed-dose group compared with adjustment-dose.
Drug Review : Oksitosin dan Misoprostol Pada Postpartum Hemorrhage (PPH) Aghnia Fuadatul Inayah; Yulistiani Yulistiani; Ayu Ratnasari; Rahmadhani Tyas Angganawati; Agus Sulistyono
Farmasains : Jurnal Ilmiah Ilmu Kefarmasian Vol. 9 No. 1 (2022)
Publisher : Universitas Muhammadiyah Prof. DR. HAMKA

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22236/farmasains.v9i1.5350

Abstract

Postpartum Hemorrhage (PPH) merupakan penyebab yang sangat penting dari mortalitas dan morbiditas ibu di seluruh dunia. Seluruh pedoman merekomendasikan oksitosin intramuskular sebagai pengobatan uterotonik lini pertama untuk semua perempuan yang melahirkan pada persalinan trimester ketiga. Pengobatan ini untuk pencegahan PPH karena kemanjuran dan keamanannya, sementara misoprostol digunakan sebagai alternatif dalam kondisi di mana oksitosin tidak tersedia atau di daerah di mana pasien tidak memiliki akses ke perawatan yang terampil. Tujuan penelitian ini untuk membandingkan penggunaan oksitosin dan misoprostol berdasarkan dosis, dan aspek farmasi yang berupa bentuk sediaan, pemberian, stabilitas/penyimpanan dan efek samping umum yang terjadi pada pasien PPH. Studi ini merupakan narrative review yang dilakukan penelusuran pustaka melalui Google Scholar, Pubmed dan Science Direct. Hasil review menunjukkan profilaksis oksitosin mengurangi kehilangan darah dan kejadian PPH tanpa hasil yang merugikan. Penggunaan oksitosin dengan Uniject juga memberikan keuntungan pada penghematan biaya. Akan tetapi, penggunaan oksitosin harus diberikan oleh tenaga profesional. Pengunaan misoprostol adalah alternatif yang efektif untuk pengobatan PPH primer. Namun, penggunaan misoprostol dikaitkan dengan beberapa efek samping sehingga diberikan apabila ketersediaan oksitosin terbatas. Dengan demikian, dapat disimpulkan pemberian oksitosin lebih diutamakan untuk PPH karena dari efek samping lebih minimal dibandingkan misoprostol.